Berry Global Group, Inc. recently announced that it is investing in a state-of-the-art Reicofil R5 asset to provide incremental capacity to serve the fast-growing Asia healthcare markets. The investment is reportedly targeted to meet forecasted market and customer growth and will be focused on high-performance applications in the desired healthcare markets.

The new asset will be installed at Berry’s Nanhai, China, facility, which is reportedly strategically positioned to serve customers in the rapidly growing Southeast Asia region. Current projections are for startup in the September quarter of 2022.

“We are committed to further partnering with our customers to pursue growth opportunities around the world,” said Curt Begle, president of Berry’s Health, Hygiene, and Specialties Division. “The added capacity achieved through this asset is a next step in advancing our market leading position in healthcare material solutions. This investment comes on the heels of the successful commercialization of the first of its kind R5 asset in Berry’s Nanhai, China, facility, serving the high-loft soft material needs of the premium hygiene markets throughout the Asia region.”

Berry reports that, once installed, the line will be critical in the manufacturing of healthcare nonwoven materials, primarily surgical drapes and gowns. For more information, visit